DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy

Phase 2

Terminated

Conditions: Head and Neck Neoplasms

Interventions: Other: MPACT

First Posted Date: 2015-06-30

Last Posted Date: 2019-10-09

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 5

Registration Number: NCT02485470

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

Early Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: MPDL3280A
Radiation: Hypofractionated Radiotherapy

First Posted Date: 2015-06-08

Last Posted Date: 2019-02-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 12

Registration Number: NCT02463994

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
University of Washington, Seattle, Seattle, Washington, United States

A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma

Not Applicable

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: Adaptive Radiation Therapy

First Posted Date: 2015-06-02

Last Posted Date: 2023-11-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 77

Registration Number: NCT02460835

Locations: 🇺🇸
Rogel Comprehensive Cancer Center, Ann Arbor, Michigan, United States

VISmodegib for ORbital and Periocular Basal Cell Carcinoma

Phase 4

Completed

Conditions: Carcinoma, Basal Cell

Interventions: Drug: Vismodegib

First Posted Date: 2015-05-06

Last Posted Date: 2021-10-28

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 35

Registration Number: NCT02436408

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers

Not Applicable

Completed

Conditions: Lymphoma
Leukemia
Brain Tumor

Interventions: Behavioral: Education information system

First Posted Date: 2015-04-06

Last Posted Date: 2019-07-29

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 59

Registration Number: NCT02409121

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

Phase 2

Completed

Conditions: Hemophagocytic Syndrome (HPS)

Interventions: Drug: Ruxolitinib

First Posted Date: 2015-03-27

Last Posted Date: 2021-01-25

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 6

Registration Number: NCT02400463

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

Not Applicable

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Other: endocrine therapy alone without radiotherapy

First Posted Date: 2015-03-26

Last Posted Date: 2023-09-22

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 202

Registration Number: NCT02400190

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Harvard University, Cambridge, Massachusetts, United States

and more 10 locations

Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel 80mg/m2 weekly x 12 weeks

First Posted Date: 2015-01-14

Last Posted Date: 2017-05-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 60

Registration Number: NCT02338115

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Autologous Stem Cell Transplant
Drug: Melphalan
Drug: Lenalidomide
Drug: MK-3475

First Posted Date: 2015-01-06

Last Posted Date: 2018-07-27

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 32

Registration Number: NCT02331368

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: peg-IFN-α
Procedure: Hematopoietic Cell Transplant (HCT)
Drug: Tacrolimus
Drug: Methotrexate

First Posted Date: 2014-12-31

Last Posted Date: 2021-10-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 37

Registration Number: NCT02328755

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy